期刊文献+

液质联用检测人体血浆中的阿奇霉素 被引量:6

Determination of Azithromycin in Human Plasma by High Performance Liquid Chromatography Coupled with Tandem Mass Spectrometry
下载PDF
导出
摘要 采用高效液相色谱串联质谱技术(HPLC—MS/MS)测定人体血浆中阿奇霉素的浓度.选用LichrospherCN柱,流动相为V(乙腈):V(水)=40:60(水中含体积分数为0.1%的甲酸和质量分数为0.1%的醋酸铵),电喷雾离子源正离子方式检测.该方法在2.34—600ng/mL范围内线性关系良好,定量下限为2.34ng/mL(S/N〉10),回收率94.13%~97.42%,基质效应92.50%~107.87%,日内和日间测定药物浓度的相对标准偏差(RSD)均小于10.O%.用该方法测定了24名男性健康志愿者单剂量口服500mg阿奇霉素试剂和参比制剂于192h内的血药浓度,并进行了生物等效性研究. A simple and sensitive liquid chromatography/tandem mass spectrometry method was developed and validated for determination of azithromycin in human plasma with erythromycin as the internal stan-dard. Chromatographic separation was performed on a Lichrospher CN column(4.6 mm× 150 mm) with a mixture of acetonitrile and water ( containing 0. 1% formic acid and 0. 1% ammonium acetate, volume ratio 40: 60 ) as mobile phase. Selected ion monitoring was specific for azithromycin and erythromycin (IS). The assay was linear over the mass concentration range 2.34-600 ng/mL and the correlation coefficients for the calibration curves ranged from 0. 997 to 0. 999. The intra- and inter-day precisions, calculated from quality control samples, were less than 10%. Protein precipitation with methanol was chosen for sample preparation method. The recoveries ranged from 94. 13% to 97.04 % and matrix effect ranged from 92. 50% to 107.87%. The method was applied to bioequivalence study after oral administration of 500 mg azithromycin to 24 healthy volunteers.
出处 《高等学校化学学报》 SCIE EI CAS CSCD 北大核心 2007年第11期2046-2050,共5页 Chemical Journal of Chinese Universities
基金 国家自然科学基金(批准号:20332020)资助
关键词 阿奇霉素 人体血浆 生物等效性 高效液相色谱串联质谱法 Azithromycin Human plasma Bioequivalence HPLC-MS/MS
  • 相关文献

参考文献9

二级参考文献28

  • 1陆润钟.Azithromycin及其相关化合物的分析[J].国外医药(抗生素分册),1995,16(2):87-91. 被引量:16
  • 2陈亦芳,李寨,郝凤兰,候平,李家泰.Azithromycin的体外抗菌作用[J].中国抗生素杂志,1995,20(3):178-185. 被引量:44
  • 3韩可勤,黄圣凯.生物等效性评价中常用统计方法的功效与样本容量[J].中国临床药理学杂志,1995,11(2):111-115. 被引量:44
  • 4张菁,郭蓓宁,张婴元.阿奇霉素临床药代动力学研究[J].中国临床药理学杂志,1996,12(2):89-92. 被引量:37
  • 5国家药典委员会.药物制剂人体生物利用度和生物等效性试验指导原则[A]..见:中华人民共和国药典(2000年版:二部)[C].北京:化学工业出版社,2000.附录193~7.
  • 6KOYTCHEV R,OZALP Y,ERENMEMISOGLU A,et al.Assessment of the bioequivalence of different formulations containing azithromycin (tablets and suspension) [J].Arzneimittelforsch,2004,54(9a):578-582.
  • 7GANDHI R,KAUL C L,PANCHAGNULA R.Pharmacokinetic evaluation of an azithromycin controlled release dosage form in healthy human volunteers:a single dose study[J].Int J Pharm ,2004,270(1-2) :1-8.
  • 8KEES F,SPANGLER S,WELLENHOFER M.Determination of macrolides in biological matrices by high-performance liquid chromatography with electrochemical detection[J].J Chromtogr A ,1998,812(1-2):287-293.
  • 9Luke DR, Fould G. Disposition of oral azithromycin in humans[J]. Clin Pharmacol Ther, 1997,61(6) :641.
  • 10Krichoff RM, Imufen H, Schacke G,et al. Determination of azithromycin in gastric biopsy samples[J]. Int J Clin Pharmacol Ther, 1999,37(7):361.

共引文献78

同被引文献49

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部